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ABSTRACT

ARTICLE HISTORY

Quality assurance (QA) guidelines are essential to provide uniform execution of clinical hyperthermia
treatments and trials. This document outlines the clinical and technical consequences of the specific
properties of interstitial heat delivery and specifies recommendations for hyperthermia administration
with interstitial techniques. Interstitial hyperthermia aims at tumor temperatures in the 40–44  C range
as an adjunct to radiation or chemotherapy. The clinical part of this document imparts specific clinical
experience of interstitial heat delivery to various tumor sites as well as recommended interstitial hyperthermia workflow and procedures. The second part describes technical requirements for quality assurance of current interstitial heating equipment including electromagnetic (radiative and capacitive) and
ultrasound heating techniques. Detailed instructions are provided on characterization and documentation of the performance of interstitial hyperthermia applicators to achieve reproducible hyperthermia
treatments of uniform high quality. Output power and consequent temperature rise are the key
parameters for characterization of applicator performance in these QA guidelines. These characteristics
determine the specific maximum tumor size and depth that can be heated adequately. The guidelines
were developed by the ESHO Technical Committee with participation of senior STM members and
members of the Atzelsberg Circle.
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Introduction
These quality assurance (QA) guidelines for the application of
interstitial hyperthermia, as presented here, were developed
upon request of the Atzelsberg Circle for Clinical
Hyperthermia, which is the Interdisciplinary Working Group of
Hyperthermia ‘Interdisziplin€are Arbeitsgruppe Hyperthermie’
(IAH) [1] of the German Cancer Society (‘Deutsche
Krebsgesellschaft’) to the European Society for Hyperthermic
Oncology (ESHO) [2]. ESHO delegated this task to the ESHO
technical committee (ESHO-TC), who formulated the guidelines with participation of experienced members of the
Society for Thermal Medicine (STM) [3].
Goal: these guidelines aim to establish a single uniform
level of quality assurance and control in hyperthermia treatments delivered in all multi-institutional studies initiated by
the Atzelsberg Circle or under the auspices of the ESHO. The
goal of this effort is to establish QA guidelines for the
CONTACT J. Crezee
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Meibergdreef 9, Amsterdam, the Netherlands

KEYWORDS

Clinical; quality assurance;
interstitial; hyperthermia

application of interstitial hyperthermia (IHT), similar to the QA
guidelines for the administration of deep and superficial
hyperthermia defined earlier [4–7] and as follow-up to the earlier QA guidelines for interstitial hyperthermia provided by
Radiation Therapy Oncology Group [8], earlier reviews on
interstitial technology [9,10] and the hyperthermia guidelines
by ESHO [11]. The technical properties and clinical practice
described in these earlier documents serve as starting point
for these updated and expanded guidelines. New in the
guidelines is more attention to the consequences of the heterogeneous temperature distributions and high-temperature
gradients during clinical interstitial hyperthermia. Furthermore,
detailed descriptions are included of standardized QA and
working procedures before, during and after clinical application, all based on modern computer technology. Results from
these earlier documents are discussed when necessary for
understanding the rationale of these new guidelines.
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The guidelines serve as the current standard to facilitate
that the application and registration of interstitial hyperthermia treatments within clinical trials follow current knowledge
and experience both from technological and clinical considerations. Consequently, participation in clinical trials requires
both implementation of these QA guidelines and strict
adherence to the specific requirements of the clinical study
protocol in order to apply hyperthermia to the defined clinical target. Storing treatment data should preferably follow a
joint standard format [12]. It is the responsibility of every
institute to characterize its hyperthermia equipment and to
make the data available to the ESHO-TC. As a follow-up to
the development of these QA guidelines and use of the
experimental and clinical information obtained via the implementation of the QA guidelines, the ESHO-TC may formulate
a list of device types with a description of the potential
tumor size and location that can be heated.
The QA-IHT guidelines in this paper are intended for interstitial devices used to generate hyperthermic temperatures
within a tumor volume that are predominantly within the
40–44  C range for 30–60 min typical duration, as an adjunct
to radiation therapy [13], chemotherapy [14], and potentially
immunotherapy [15]. Hyperthermia delivered in this fashion
is targeted toward direct cytotoxicity of nutrient deprived
and hypoxic cells, and indirect cell kill by radiosensitization
and chemosensitization [16]. Although not covered in this
document, similar devices can be used to deliver thermal
ablation therapy, where temperatures exceeding 50–55  C
and a lethal thermal dose (>240 CEM43  C) are targeted
throughout the tumor and surrounding margin for producing
irreversible tissue destruction. The choice between applying
ablation or hyperthermia treatment is guided by tumor sitespecific considerations and clinical practice.
In particular, these QA-IHT guidelines summarize the characteristics of interstitial heating and cover both technical and
clinical aspects of applying IHT and procedures to characterize the heating capabilities of IHT devices. When the QA-IHT
guidelines states ‘must’, strict application is required whereas
when it states ‘should’, implementation is strongly
recommended.

than placed within natural body cavities like cervix, bladder,
esophagus and urethra. Benign prostatic hyperplasia may be
treated with intraluminal transurethral microwave thermotherapy in the 45–60  C range [17]. Intracavitary and intraluminal applicators may have active lengths similar to
interstitial applicators but are generally not used in multiapplicator arrays and the diameter can be larger, up to 30 mm,
depending on size of the cavity involved. These QA guidelines are intended for interstitial hyperthermia, although
parts may be applicable to intraluminal and intracavitary
hyperthermia which may be considered a special case of
interstitial heating using only one applicator.
Although many considerations for QA-IHT are directly
comparable to QA considerations for other hyperthermia
treatment approaches, there are two major differences which
hamper direct transfer of knowledge/experience from external heating technologies. For external hyperthermia, the
heating and radiotherapy delivery devices are used independent of each other. In contrast, the clinical use of IHT systems is usually closely interlaced with brachytherapy as both
treatments use the same catheters. Hence, power deposition
in IHT is confined to the tumor region avoiding the risk of
treatment limiting hot spots in surrounding normal tissues,
which should lead to better tumor coverage. The comparatively thin rim of heated tissue margin around the heated
tumor volume creates a risk of heterogeneous and lower
temperatures in the tumor periphery due to the cooling
effect of incoming normothermic blood. Due to the steep
thermal gradient associated with highly localized IHT heating, achieving acceptable tumor temperature uniformity is
possible only with careful placement and spacing of the IHT
applicators and with adequate temperature control to
achieve a sufficiently high temperature between the applicators without overheating the tissue close to the applicator.
Maintaining appropriate insertion lengths and parallel spacing between catheters, sufficient implant catheters in the
periphery, along with adequate catheters for thermometry,
are critical points of which the radiation oncologist and surgeon must be aware during catheter implantation.

Part I. General definitions

I-B definition of a minimum thermal dose requirement
for an interstitial hyperthermia treatment

I-A definition of IHT
Interstitial hyperthermia is a heating method using arrays of
needle-shaped applicators implanted directly or applicators
inserted within catheters that are implanted into the target
volume. Commonly treated tumor sites include brain, breast,
head and neck, cervix, prostate and bladder. Interstitial applicators have a typical active length of 4–10 cm and a diameter of 1–2 mm. Due to steep radial fall-off of energy and
blood perfusion, heating penetration is limited for most
modalities to 5–10 mm radius of tumor tissue around each
applicator, often dictating that multiple applicators be used.
Interstitial heating techniques are based on the same
heating principles as intracavitary and intraluminal techniques, but energy is delivered from interstitial needles or
catheters implanted percutaneously into the tumor rather

A fundamental premise of these QA guidelines is that the
proven effectiveness of hyperthermia in clinical studies relies
exclusively on its thermal effect on tumors, which is dependent on temperature and time [16,18–21]. For this reason,
interstitial hyperthermia treatments must be conducted using
hyperthermia devices that are technically capable of providing controlled heating of the specific target volume to the
required thermal dose range (as defined in part II) while minimizing dose to surrounding critical normal tissues and adjacent normal organs (‘organ at risk’ – OAR). The target
volume and organs/areas at risk are to be defined by the
responsible oncologist using imaging studies and/or physical
examination.
Current literature shows clinical evidence that the benefit
of hyperthermia exists only when hyperthermia is applied in
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combination with chemotherapy and/or radiotherapy.
Different protocols specify different thermal dose goals
depending on combinations with other therapeutic agents
like radiation or chemotherapy and location in the body. The
clinical protocol also defines the time interval between the
chemotherapy/radiotherapy and hyperthermia treatment session, aiming for optimal sensitization of chemo- and radiotherapy. In current practice, chemotherapy is applied just
before or simultaneously with hyperthermia, while radiotherapy is generally applied within 1–4 h of hyperthermia to
enhance therapeutic ratio, that is, obtain significant thermal
enhancement in tumor while avoiding enhancing normal tissue side effects [22]. In rare cases when technically feasible,
external beam radiotherapy and interstitial hyperthermia can
be applied simultaneously [23] to achieve the potentially
highest thermal enhancement possible [22,24].
In particular, a good interstitial hyperthermia treatment is
defined as heating the target volume above the minimum
prescribed thermal dose while maintaining critical normal tissues below the maximum prescribed normal tissue thermal
dose. At each hyperthermia session, the goal temperature of
40–44  C in the target volume should be aimed for over a
period of 30–60 min. This means that temperatures exceeding 44  C can occur very close to the applicators due to the
steep temperature gradient characteristic of interstitial heating. Interpretation of the measured temperatures during
interstitial hyperthermia requires special consideration of the
steep energy decay and precise location of temperature sensors (see Section II-E).

Part II. Clinical considerations
II-A clinical requirements on heating devices
An interstitial hyperthermia system should be capable of
increasing the temperature in the majority of the target volume to the desired therapeutic level of 40–44  C, with possibly higher temperatures (44  C to 48  C) localized in small
volumes immediately adjacent to the applicators. These
higher temperatures adjacent to the applicators should be
within the tumor target volume. To achieve this, an individual applicator should be able to deposit at least 0.5W/g in its
subvolume of the implant volume, see Section III-B for details
[25]. In order to produce more uniform heating, it should be
possible to control the output power of individual applicators independently between 0% and 100% of maximum output.
IHT catheters are generally selected for use with properties suitable for brachytherapy, which only partly coincide
with requirements for hyperthermia. A property very relevant
for hyperthermia is the proportion of applicator power that
is absorbed in the catheter wall. Excessive self-heating of
catheters leads to a significant change of the physical mechanism of energy transfer. For radiative EM approaches, the
catheter should be made from electromagnetically (EM) lossless or lowloss materials like polytetrafluoroethylene (PTFE),
polyethylene (PE) or silicone. Most applicator designs are
matched to specific catheter materials and diameters in
order to achieve the desired power deposition patterns.

Thermal conduction hot sources also require specific catheters to achieve the correct temperature in tissue.
To generate more uniform heating independent of applicator geometry, noncoherent or asynchronous excitation of
multiple applicators is generally preferred. Special care must
be given to interapplicator spacing, maintaining greater than
5 mm separation, in order to minimize cross-coupling and
interaction between adjacent applicators and to achieve a
contiguous therapeutic temperature distribution above 40  C
iso-temperature level across all target tissue between
implanted sources. Due to the small diameter of interstitial
implants and sharp radial fall-off of the energy deposition
around each device, the temperature distributions throughout the target are more heterogeneous compared to superficial heating, with generally unknown peak temperatures
located at the surface of the sources and valleys or dips in
temperature between implants. Use of phase steering to correct for cold spots is technically possible after careful hyperthermia treatment planning but difficult to implement
reliably in clinical practice as often positioning is imprecise
and insufficient thermometry is available for feedback.
Hence, synchronous excitation of applicators is generally not
preferred. Implanting of additional catheters to improve thermal dose distribution and allow for adequate thermometry
should be considered. The important factor for a quality
treatment is to maintain a minimum therapeutic temperature
throughout the target, and thus, careful preplanning and
monitoring of temperature in the valleys between sources is
critical to successful treatment. Furthermore, care should be
taken regarding placement of applicators too close to the
body surface or bony structures to avoid perturbation of
expected applicator SAR pattern, feedline heating, and normal tissue toxicity.

II-B overview of existing (minimal) invasive heating
technologies
An overview of interstitial, intraluminal and intracavitary
heating technology can be found in Appendix B and in
[9,26,27], which describe nine distinct technologies for heating tissue with miniature implantable heat sources. These
documents summarize design concepts and typical performance for numerous implementations of these nine technologies which have resulted from University prototypes and
commercial production. The most common devices are: (i)
coaxial cable mounted microwave (MW) antennas [28] which
have been manufactured in a variety of monopole, dipole
and helical coil configurations; (ii) laser-irradiated fiberoptic
diffuser crystals [29]; and (iii) radiofrequency (RF) electrodes
that couple either resistively [30,31] or capacitively [32–34] to
surrounding tissue. For hyperthermia applications where
temperatures are restricted to a narrow 40–44  C window,
interstitially implanted sources heat roughly 5–10 mm radius
cylindrical or ellipsoidal volumes so must be implanted in
arrays with 10 mm or less spacing. In the special case of
using microwave synchronous phase array mode, the spacing
can be 20 mm. The advantage of such a configuration is that
catheters of the 10 mm spacing brachy implant can be left
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nonoccupied to be used for temperature probes providing
relevant feedback for RF-power control per applicator. When
high-density implant arrays close to 10 mm spacing are clinically feasible, thermal conduction only hot sources may be
used to produce relatively uniform heating within the interior of an array away from the periphery. Thus, there has
been considerable investigation of hot source techniques like
needle- or catheter-based hot water perfusion (HWP) [27,35],
DC resistance wires (RW) [36], and ferromagnetic seeds (FMS)
[37,38] which are unique in that no externalized connections
are required to couple energy from an external magnetic field.
Some of the above approaches have no provision to
adjust heating along the length of the implanted source
which limits homogeneity of heating and localization of heat
to just the tumor volume. To provide real-time adjustment of
heating along the implant length, other approaches have
been investigated [39–41]. Of the currently available interstitial systems, the most adjustable patterns are possible from
capacitive coupled bipolar RF electrodes [32,42] and linear
array tubular ultrasound (US) transducers in either direct
coupled [43] or catheter-cooled [44] configurations. In particular, the ultrasound array applicators can provide precise
control over the angular as well as axial distribution of the
SAR [45]. Of the various technologies for interstitial hyperthermia, only MW antennas are commercially available; all
other devices are products of academic research groups.
Somewhat larger diameter sources based on the same
technologies as mentioned above have been used successfully for heating tissue surrounding natural body cavities
(e.g., urethra, rectum, esophagus, bile duct). This intracavitary
heating technology has been reviewed previously [10,46,47].

II-C specific considerations for IHT-treated tumor sites
Experience with the clinical application of IHT shows the
need for attention to a number of physical and (thermo)
physiological aspects of treatment for specific tumor sites.
The distribution, alignment and spacing of implanted catheters are often determined by the requirements and constraints for brachytherapy, and the resulting implant tends to
be suboptimal for hyperthermia. Spatial control over the
temperature distribution is achieved by power control of
individual applicators. Axial steering along the length of individual applicators is not possible for many of the IHT applicators. Moreover, poor alignment and heterogeneous catheter
spacing can cause hot and cold spots within the implant,
which might be enhanced when using coherent or synchronous power to drive different applicators. Proximity of anatomical structures with very low-power absorption like bone
and air/gas surface can also cause hot spots; this should be
taken into account when implanting the target region. Very
localized hot spots are acceptable as long as they are within
the macroscopic tumor and do not lead to pain complaints.
High perfusion levels are a major issue in many tumor
sites, including head and neck, brain and prostate where
high perfusion levels can produce significant temperature
heterogeneity [37]. Movement and changes in catheter
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alignment, applicator insertion, and thermometry positioning
are other aspects that should be monitored and controlled.
Heating brain tumors requires more caution to avoid toxicity in surrounding thermally sensitive normal brain tissue as
patients are generally incapable of sensing either pain or
excessive temperatures in the brain. Monitoring of brain temperatures in fully awake patients is critical so the patient can
report unusual sensations or neurological perturbations,
which correspond to the brain region treated. In some cases,
patients may respond with seizures during heat treatment,
especially in cases where the tumor is pressing upon motor
control areas of the brain. Some brain tumors, for example,
glioblastoma, are associated with microscopic infiltration
extending out into the surrounding normal brain tissue,
necessitating implantation of a comparatively large margin
of normal brain around the macroscopic tumor [23].
For base of tongue tumors, the main critical structures are
bones close to the target volume where excessive temperatures should be avoided. Additionally the temperature distribution can be heterogeneous due to heterogeneous
perfusion in this region and nonparallel catheter placement.
When curved catheters (e.g., loops) are used with an extreme
curvature, proper positioning of the hyperthermia applicators
can be compromised. Further, care must be taken to ensure
that catheter insertion and applicator insertion length are
sufficient to produce the desired power deposition pattern
while avoiding skin or entry site burns.
In the case of breast tumors, excessive temperature
should be avoided in critical tissues such as skin overlying
the breast, scar tissue, surgical skin flaps, and bony structures
if the target volume is close to the chest wall. For most
tumor sites, the tips of the brachytherapy catheters are
placed at the distal edge of the tumor, facilitating correct
positioning of the hyperthermia applicators as the active
heating region of most applicators also starts at the tip.
Correct positioning of applicators relative to the tumor target
requires more attention in the case of breast tumors
implanted with catheters exiting the skin on both ends and
having variable amount of normal tissue overlying the tumor
target. Potential movement of the applicators during treatment is also an issue requiring precaution. Occasionally,
highly curved (e.g., looping) catheters are implanted for
brachytherapy in breast and head and neck cancers, which
may cause passage, positioning problems, and possibly
undesirable SAR patterns for hyperthermia as discussed earlier for base of tongue tumors.
The critical structures for prostate tumors are the urethra,
neurovascular-bundles, bladder neck and wall, penile bulb,
and bowel and rectum. Causing damage to these structures
during catheter placement or treatment delivery should be
avoided. These structures are close to, or in the case of the
urethra, inside the target volume so a minimum therapeutic
temperature of 40  C is necessary although excessive temperatures >45  C should be avoided.
Generally, the catheters are placed and fixed using a template during the entire treatment. This template is often
fixed to the target region using metallic needles. These
metallic fixation needles are recommended to be removed
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Figure 1. Schematic workflow of interstitial hyperthermia which consists of preplanning, catheter implantation, reconstruction, hyperthermia treatment planning,
treatment with heat up phase (I), therapeutic phase (II) and cool down phase (III), and finally documentation.

during hyperthermia to avoid unwanted excessive heating at
these metallic structures. Alternatively metallic fixation needles can be replaced with plastic anchoring catheters [48].

planning should take the implant requirements for both
radiotherapy and hyperthermia into account. A catheter
spacing of 10 mm is optimal general practice for
both modalities.

II-D recommended IHT treatment delivery
Figure 1 shows the workflow of IHT, which consists of: preplanning, catheter implantation, reconstruction, hyperthermia
treatment planning, treatment with heat up phase (I), therapeutic phase (II) and cool down phase (III), and finally documentation. The target volume is always defined by the
responsible clinician. Definition of the tumor volume, adjacent normal organs, OARs, and large vessels is one of the
most important aspects of the treatment planning process,
so it should incorporate the information from clinical examination and radiologic studies (US, computed tomography (CT),
magnetic resonance imaging (MRI), Positron-emission tomography-computed tomography (PET-CT). CT or US guidance is
used to place the catheters into the tumor target volume. In
case of combining brachytherapy with hyperthermia, the
clinical target volumes for both treatments should be the
same. The geometry of the implant catheters should take
into account brachytherapy physics, as well as technical
properties of the heat sources [9] and the required number
and position of thermometry probes.

Preplanning
Pretreatment planning involves definition of the target volume by the responsible clinician, more specifically the number, location and orientation of IHT applicators and
thermometry to cover the desired target volume, taking into
account the required applicator alignment, spacing and margins needed to ensure adequate tumor heating. Both
patient-specific and generic nonpatient-specific planning
using published implantation guidelines for specific techniques are acceptable [8,9]. Interstitial hyperthermia is generally applied using catheters implanted for brachytherapy, so

Catheter implantation
a.

Catheters for applicators should use materials compatible with the hyperthermia technique used, for instance
plastic catheters without self-heating should be used in
conjunction with EM techniques [49]. Catheters should
be distributed homogeneously and parallel orientation
throughout the target volume including the periphery
to avoid hot spots as well as areas of underdosage. The
goal temperature is 40–44  C throughout the target volume combined with sparing of organs at risk and critical
structures. Homogeneity of heating will be improved by
reducing the spacing between catheters. Alternatively,
accepting higher temperatures close to the catheters
will help to reach the minimum temperature.
b. Catheters for thermometry should use the same materials as catheters for applicators. They should be
placed at:
– representative locations for best sampling of target
temperature.
– expected cold regions, that is, at the periphery and at
target locations at a large distance from applicators
– close to critical structures
– expected hot spots
When single point thermometry probes are used, mapping
of the probes in the catheter should be applied, when possible. However, continuous multipoint thermometry is preferred over thermal mapping. The recommended number of
thermometry locations is given in Table 1, although a larger
number of thermometry locations matching or exceeding
number of independent applicators is preferred. A good
example of a thermometry scheme is given by Kukielka
et al. [50].
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Table 1. Recommended minimum number of temperature probes.
No. of heat
sources

No. of tumor volume
representative probes

No. of peripheral
probes

No. of probes in
the center of source
interspace

4–6
1
1
0
7–10
1
1
1
10–16
2
1
2
17–30
3
2
2
>30
3
2
3
The proposed number of temperature probes is the result of careful consideration of the optimum use of available catheters to insert sufficient applicators to obtain a high quality temperature distribution vs. a hesitance to insert
additional catheters that provide only temperature data.

Reconstruction
Reconstruction of the treatment setup should be performed
by 3D-imaging with CT, MR, or US with the patient in treatment position including the IHT catheters or applicators.
Implant catheters should be visualized for proper tracking
and localization, using dummy inserts if needed to recognize
the catheter positions. The gross tumor volume (GTV) and
hyperthermia target volume (HTV) should be defined.
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Documentation
Treatment data to be recorded include temperatures of
tumor and normal tissues at risk, tumor thermal dose,
applied power to each applicator, temperature and flow of
the cooling medium (if applicable), and operator and patient
comments (e.g., pain). Calculating and recording temperature
parameters T50 and T90, the temperatures achieved in 50%
and 90% of measured (tumor-related) points, respectively,
and CEM43T90 (CEM for ‘cumulative equivalent minutes’) is
recommended, but challenging in view of the heterogeneous
temperature distribution during IHT. Temperatures recorded
using dedicated thermometry catheters will generally provide
the minimum target temperature. Accurate dose distribution
data are needed to obtain reliable T90 and CEM43T90 correlated with clinical response. The full list of parameters to
document is given in Section IV-B.
Throughout planning and treatment delivery, HT should
be done in such a way as to minimize impact on standard
brachytherapy practice.

Part III. Technical considerations
Planning

III-A key characteristics of interstitial applicator devices

Definitive treatment planning: The actual/updated gross
tumor volume (GTV) and hyperthermia target volume (HTV)
should be defined in the 3 D patient data set. Hereafter, the
physicist/engineer can calculate the tissue insertion length of
each catheter, the HTV along that length, the definite location of the applicators and temperature probes together
with the steering parameters. If necessary, an offset to the
applicator or thermometry insertion can be applied to match
insertion depth to target volume.

Interstitial applicators in use today consist of MW antennas,
capacitively coupled radiofrequency catheter-based electrodes (RF-CC), resistively coupled radiofrequency local current
field electrodes (RF-LCF), and ultrasound transducers. In general, these devices deposit energy within a limited volume of
tissue close to the heating device(s). The operating principles
of various systems for interstitial heating have been reviewed
previously [9,51–53] and are summarized in Appendix B
and C.
Heating uniformity within an interstitial implant array is
highly dependent on: (i) modality and technical properties of
the applicator used; (ii) implant spacing and alignment; and
(iii) applicator position within each needle or catheter
implant relative to the skin and other applicators. The comparison of critical implant characteristics given in Table 2 for
four different interstitial heating techniques provides some
guidance in selecting the appropriate technique for a specific
tumor indication.
As indicated in Table 2, RF-LCF techniques are most sensitive to parallel alignment of sources and MW antennas are
more sensitive to alignment than US segmented linear array
applicators that can be adjusted in power along the length
to accommodate variable distance between implants. An
important factor determining the required spacing is the
characteristic heat penetration depth (PD) of the applicator.
The PD of RF techniques is conservatively defined by 1/r2
falloff. Theoretically, higher PD can be achieved in the central
part of the target volume with an array of multiple parallel
MW applicators, if used in (nonrecommended) coherent
mode. A special case exists for synchronous or coherent
phase modes using a 20  20 mm implant utilizing the nonoccupied catheters for temperature measurement and feedback. To cover larger target volumes, ultrasound devices
with the highest PD shall be preferably used to minimize the

Treatment
The operator should have all relevant data to control the
treatment (temperature, dose, power, time - history) presented in the graphical user interface (GUI). Safeguards to
detect and prevent malfunctioning of equipment, such as
reflected power monitoring, should be present. Applicators
and temperature probes are placed in the catheters.
Hereafter, the treatment starts using low power. During the
first 10 min the power is stepwise increased, after every
power increase the temperatures and vital signs of the
patient are monitored. The remaining treatment time after
reaching steady-state (temperature T > 40  C) should be
between 30 to 60 min. Temperatures should be recorded at
least every minute. If temperature mapping is used a cycle
time for the temperature profiles of at most 5–10 min is recommended. Recording the temperature decay for several
minutes after turning off the power is recommended. Most if
not all patients will be on epidural and pain meds already,
but during ‘breakthrough’ discomfort additional meds can be
given or the applied power distribution can be altered or
reduced if deemed necessary from patient feedback,.
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Table 2. Comparison of device characteristics for four interstitial heating modalities.
Factor

RF-CC

RF-LCF

MW

Ultrasound

Longitudinal SAR uniformity
Longitudinal SAR adjustability
Robustness of SAR to non-parallel alignments in array
Spacing between applicators [mm]
Thermometry at catheter feasible with applicator insertedc
Catheter gauge
Compatible with brachytherapy catheters
Compatible with
- metal thermometry probes
- nonmetal thermometry probes

þþ
o
o
10–15
þ
15 G
Yes

---10–15
na
15 G
Yes

þ
/þa
o
10–15; 20b
–
15 g
Yes

þþ
þþ
þ
15–20
o
13–14 G
No

/þd
þþ

–
þþ

/þe
þþ

þ
–

The performance is indicated by following grades: þþ: very good; þ: good; o: fair; -: poor; –: very poor.
’-‘ applies for MW dipole antennas; ‘þ’ applies for MW helical coil antennas.
for coherent use the spacing can be 20 mm.
c
although feasible it is rarely used and mostly indicates only maximum temperature; not applicable (na) for RF-LCF as it uses long metal needles with high thermal conductivity.
d
when placed in dedicated thermometry catheter.
e
for temperature probes placement perpendicular to E-field direction:  no RF-filtering; ‘þ’ with RF-filtering.
a

b

number of heating elements needed. This increase in PD justifies an increase in required implant array spacing from 1015 mm for RF-CC/RF-LCF/MW techniques to 15–20 mm for US
transducers, as listed in Table 2. The PD of MW antennas can
be improved by selecting a lower operating frequency up to
a certain limit [54]. Some techniques apply internal cooling
to reduce the maximum temperature at the applicator surface. This allows the operator to raise the applied power
without overheating the applicator surface, effectively
increasing the PD by a few mm. This allows a corresponding
increase in implant spacing over non-cooled applicators. A
practical implication for this approach is that maximum temperature Tmax cannot be acquired in or near the applicator.

III-B characterization of heating properties
The implant/applicator is usually characterized as a single
device, but clinically applied in an array of applicators. An
IHT system should be capable of increasing the temperature
throughout the target volume to the desired therapeutic
range of 40–44  C. To achieve this, an individual implant/
applicator should be able to deposit at least 0.5W/g in its
subvolume of the implant volume [25,55]. Characterization of
the applicator’s heating properties should be performed
annually and consist of measuring the heating pattern
(Figure 2(b)) and its efficiency (Figure 2(c)).

(1) Single applicator
Prior to clinical use, the properties of the IHT system must
be characterized. First, it has to be demonstrated whether
the effective heating length (EHL) is sensitive for insertion
depth. The minimum dimension of the experimental setup
to characterize the IHT system are shown in Figure 2(a).
Therefore the temperature pattern must be measured for
two different insertion depths, for example, 5 and 25 mm
between the phantom surface and the active part of the
applicator, in a split muscle equivalent phantom used in
combination either with an IR camera (preferred) or with
liquid crystal film [56] which both need calibration before
use, with a resolution of ±0.1  C and relative accuracy
0.05  C; spatial resolution 0.5–1 mm [7] (Figure 2(b)).

These patterns should be available for the physicist prior to
geometric planning. EM field measurements using E-field
probes is not recommend, due to severe limitations with
spatial resolution [57,58]. Furthermore, a calorimetric measurement to determine efficiency of the applicator must be
performed as described by Wilkinson et al [59] (Figure 2(c)).
Knowledge of applicator efficiency is mandatory for hyperthermia treatment planning or setting power output per
applicator using synchronous or coherent arrays.
In general MW, RF-CC and Ultrasound interstitial applicators are used without counter electrodes. Only for RF-LCF the
application is mostly with a single ‘hot’ electrode and a large
counter electrode outside but against the body surface. For
all these cases, the characteristic heating properties can be
assessed as described in next sections. In rare cases, RF-LCF
heating is achieved by using two internal electrodes. For this
special case, the characteristic heating properties can also be
assessed using the description below, but the single applicator has to be replaced by the dual electrode setup and the
diameter of the phantom cylinder has to be doubled. Hence,
the picture in Figure 2(b)) holds two electrodes with heating patterns.

Temperature rise criteria for adequate heating
An interstitial heating applicator is considered adequate/
appropriate if a temperature rise (TR) of 6  C above the starting temperature can be achieved in 6 min in a muscleequivalent phantom [7], around the applicator at 5 mm, in
general a distance equal to half the implant spacing,
Figure 2(b).
The effective heating length depends on the applicator
design and can be determined using the measurement
described in section III-B (1). The EHL is characterized by a
thermal profile in the vertical plane, as shown in Figure 2(b).
Similarly to Emami et al [8], the EHL is defined as the length
at which the temperature rise (TR) is 50% or more of the
maximum TR (i.e., temperature difference DT  3  C) obtained
a constant distance of 5 mm from the applicator. The phantom can be cylindrical as shown in Figure 2, or flat but
should be sufficiently large to show the entire heating pattern.
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Figure 2. The two main experimental setups to characterize the heating properties of an interstitial applicator. (a) Schematic setup to determine the effective heating length and the average temperature rise (aTR) in muscle equivalent phantoms, (b) Determination of the effective heating length in a solid phantom and using
infrared imaging (DTmax  6  C), (c) Calorimetric setup to determine the applicator efficacy in a liquid phantom for 6 min heating time. The temperature–time profile must be measured 5 min before and after the heating and continuing during heating while continuously homogenizing the liquid to obtain the correct average
temperature. The minimum average DT must be 6  C.

Note that besides characterizing the temperature distribution, the effectively applied power must be measured annually. This can be accomplished with a calorimetric method
using a cylinder of which the diameter depends on the heating device (Figure 2(c)). The diameter of the cylinder should
be much larger than the implant spacing to reduce the
effects of the outer boundary on the measurement; and
>30 mm minimum irrespective of applicator type.
Theoretically, it seems possible to calculate the total
absorbed power from average temperature rise (aTR) measurements, but this approach has limited accuracy since it
includes self-heating of the applicator as well as the EM
deposited energy.
Thus Figure 2(c) shows the appropriate setup for calorimetric/effective power measurements. The applicator within
the planned brachytherapy catheter is immersed in a
Styrofoam isolated cylinder of given diameter with a length
of a liquid muscle-equivalent phantom [60] matching the
active length of the applicator, where the phantom should
extend 15 mm before and after the active part of applicator.
The initial temperature of the phantom must be known, typically at room temperature or other stable uniform temperature. The maximum power is applied for maximally 6 min to
achieve at least a 6  C temperature rise. As an example: to
increase the temperature of a saline volume by 6  C during a
6 min heating time an average SAR of 70 W/kg is required.
For a 3 cm diameter cylinder that is 10 cm long (i.e., a volume of 70.9 cm3 and a weight of 0.0709 kg), this translates in
an applied power level of 5 W. The aTR in the phantom is
measured before and after by a temperature probe following
good mixing of the liquid to obtain a homogeneous

temperature. The effective power emitted by the applicator
can be calculated from the relation
Pa ¼ q  cw  V  dT=dt; ½J=s ¼ W;
in which Pa is absorbed power, q is the density and cw is the
specific heat capacity of the muscle-equivalent saline water,
V is the volume, dT the temperature increase, dt is the duration of heating. Alternatively, if other liquid media are used
the calorimeter can be calibrated by a resistance wire heating element, and direct current (DC) and applied voltage
measured to provide dT per unit power deposited.

(2) Array of applicators
It is important to verify to which degree applicators are performing independently regarding heating pattern and power
output of each applicator, and whether these remain stable
and controllable when other applicators power channels in
the array are switched on or off. Such a test should be done
with an asynchronous or incoherent phase mode for these
channels. Generally, each applicator is operated by a separate, independently controlled power control channel.
Verification of this independence is particularly important
when multiple applicators are connected to a single power
channel, for example, through a power splitter or similar
device. The setup shown in Figure 3 should be used to test
and verify the stability of the heating pattern of applicators
within an array as individual applicator or part of an applicator array operated by a single power control. LCF applicators
are more sensitive for misbalance when multiple applicators
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Figure 3. Setup to verify independent performance of three applicators in an array. Experiments are required for three configurations with a different combination
of active applicators. (a) Setup to test the independence of the applicators and their generators, consisting of three applicators, each 20 mm apart, and three temperature probes indicated in black, each recording the temperature at 5 mm of the active section of one applicator. (b) Example showing temperature distributions
in the horizontal plane at the position of the maxima of Tmax when one, two or three applicators are switched on. Green dots indicate power on, red dots
power off.

are operated by a single power control than MW applicators
using a calibrated power divider.
The first test involves the temperature distribution in the
horizontal plane through the maxima of Tmax when all
applicators are switched on as depicted in Figure 3(b).
This requires a phantom filled with a muscle equivalent
gel which can be split at the mid horizontal plane to permit recording of the temperature distribution using a
thermographic camera as outlined in the superficial
hyperthermia guidelines [6,7].
The test of the stability of the heating pattern of applicators and their generators is performed using an implant
of three applicators inserted in a phantom filled with a
muscle equivalent gel as depicted in Figure 3(a). A temperature probe is inserted at 5 mm distance from each
applicator to monitor the effective output of each applicator. Applicators should be switched on and off in different configurations with the objective to establish that the
effective power output of each applicator remains stable
independent of the on/off status of the other two applicators. In this case, the RF-LCF applicators must be operated as a unipolar system with a large ground plate
connected to tissue. In systems using multiple applicators
per power channel, the applicators should be connected
to a single channel as well as distributed over different
channels. An example is given for three applicators. We
will compare the effective output power by continuously
measuring the temperature rise close to the first applicator during 3 minutes of power on for three settings: 100,
101 and 111. For systems with a minimum measured
temperature, for example, 29  C for the BSD 500, the
phantom will need to be prewarmed so that the stated
rise rate can be observed. The first experiment is the control measurement with one applicator switched on

(setting 100). In the second experiment, the first and third
applicators are switched on (setting 101). Any change in
effective output power as a result of switching on these
applicators indicates an influence of the generator as the
mutual distance of the first and third applicator is 40 mm,
too large for direct interference between the applicators.
Finally, in the third experiment, all three applicators are
switched on (setting 111). This final measurement may
also establish a more direct interference between applicators if switching on of this applicator at a closer distance
has more impact than switching on the furthest applicator. The test should be performed as a single experiment,
that is, without moving applicators and temperature sensors. A variation less than þ/-20% for each temperature
sensor/applicator pair within all three experiments is considered acceptable. The forward, reflected, and net power
should also be recorded for each applicator and test situation, and used for consistency. This procedure should
also establish that the output is indeed zero when an
applicator is switched off.
For testing an array of three applicators that share the
same RF power channel with a power divider or when an
array of three applicators are operated in a phase synchronous mode, the simultaneous operation of all three applicators with equal RF power should be tested to verify that the
measured heating rates do not vary by more than ±20%. If it
is not possible to switch connections to different applicators
of a power divider using a single channel than the applicator
cables should be connected or disconnected from the output
of the power splitter. For such a case, the input power to
the power divider would need to be changed so that the RF
power to each of these applicators would be the same. A
synchronous phased array of three applicators can have RF
power of individual channels switched on or off, but for such
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a test the temperature sensor of the central applicator may
have a higher heating rate compared to the perimeter applicators due to the synchronous phase additive effects when
all 3 applicators are operated.

III-C benefits of 3 D treatment planning
Although 3 D hyperthermia treatment planning systems are
scarcely used as a routine part of the interstitial hyperthermia workflow, they have great potential to increase the
insight and understanding of the quality of the applied heat
distribution. Phantom measurements are generally unable to
produce quantitative metrics like T10, T50, and T90, whereas
these parameters are readily calculated with treatment planning systems. The benefits of planning software are especially useful in cases of irregular implants which deviate from
equally spaced implants, or when insertion depths are variable. Simulations can help to determine the required applicator spacing for optimal target heating. If the insertion depth
is shallow for a particular source, care must be taken to
ensure that the SAR profile is as expected and not unintentionally preferentially heating tissue proximal to the target
(e.g., bulb of penis, vaginal wall), or skin surface around the
entrance site. Hyperthermia treatment planning is generally
invaluable for initial evaluation of novel interstitial hyperthermia applicators or implant configurations.
For microwave heating using commercial systems, built-in
planning tools can be used to simulate heating according to
a user defined placement of the applicators and adjusted
phase and power settings. In general, an important aspect
for treatment planning in interstitial hyperthermia is accurate
modeling of the applicators. For capacitively coupled interstitial electrodes, a grid-independent representation allows an
accurate description of irregular implants in heterogeneous
tissue [61]. Available techniques for modeling interstitial
ultrasound devices have been reviewed by Prakash et al.
[62]. In multi-element systems, the interaction between the
individual elements has a substantial impact on the achieved
temperature distribution. For instance, a graded-mesh finitedifference time-domain (FDTD) code, together with an alternate-direction-implicit finite-difference (ADI-FD) solution of
the bioheat equation, were used for studying arrays of
sleeved-slot antennas imbedded in a brain-equivalent phantom [63]. Patient-specific temperature-based optimization
techniques are being developed for these complex systems
[64] and can be expected to improve future treatments.
At this time, the use of more detailed forward and optimization-based treatment planning systems for interstitial
hyperthermia–is limited to a few academic centers that study
specific patient cases with, whenever possible, validation of
the predicted SAR/temperature distribution with measurements made during the patient treatment [65,66]. From
these experiences, recommendations for treatment have
been formulated in the literature for some general cases
(e.g., implant technique, proximity of bone, insertion depths,
synchronous versus asynchronous operation) that can be
applied by the hyperthermia community [66,67].
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Generic pretreatment planning is the minimum requirement and most basic form of planning system. This involves
computing the SAR and temperature distribution in an
equally spaced implant of applicators placed in an (semi)
infinite (half) space, assuming appropriate homogeneous tissue properties and perfusion. The characteristics of the heating device for various insertion depths into soft tissue need
to be accounted for. The reliability of generic planning is limited, but tumor temperatures will not be overestimated if
worst case assumptions are made regarding tissue and perfusion properties, for example, assuming the maximally
increased tissue perfusion rate valid in response to hyperthermic temperatures. This generic pretreatment planning is
very useful to derive generic rules for implant properties
including active applicator length, spacing and location. If
available, individual patient-specific treatment planning is
recommended using relevant anatomical data with perfusion
and tissue properties acquired using CT, MRI or
US [64,67,68].
In clinical application, computer simulations are useful to
complement actual measurements and thereby estimate the
indexed temperatures T10, T50 and T90, particularly in view
of the high gradients, small heated volume, and potentially
complex interactions within multi-element systems.
Nevertheless it is important to take into account the
uncertainties and limitations of the temperature simulation
in the planning systems.

IV. Protocol compliance, staff and documentation
IV-A demands on personnel
Hyperthermia is a multidisciplinary treatment involving complex interrelated clinical and technical aspects. It requires
input and close cooperation of radiation oncologists, medical
oncologists, medical physicists, engineers, technicians, nurses
and in some cases surgeons and anesthesiologists.
Recommendations and responsibilities for all hyperthermia
treatment staff, with the exception of surgeons, are summarized in [4,69]. Local and country-specific regulations must
be respected.

(a) Hyperthermia training
For the staff members who actually apply the interstitial
hyperthermia practical training in the form of active participation at an established hyperthermia center is required, in
addition to their main qualification. Adequate practical training is defined as at least 10 treatment sessions be performed
with the heating system in 3–5 different patients, under the
guidance of an experienced user. If the person in training
has experiences with other hyperthermia modalities (at least
1 year superficial/deep HT), the required training reduces to
five treatment sessions. It is recommended that the training
period is completed in 6 months. Staff members who just
take care of the patients’ well-being and are not directly
involved in the application of the interstitial hyperthermia
need only a basic training on the principles hyperthermia
and the possible physiological effects of interstitial heating.
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A modified training procedure can be discussed with ESHO
in case of severe practical obstacles, for example, the
absence of an established interstitial hyperthermia institute
within a reasonable distance.

thermometry, monitoring of patient vital signs during therapy, administration of analgesics and pain medications, etc.).
When properly trained according to the physicist or treatment technician requirements above, the nurse may perform
the hyperthermia treatment.

(b) Physicians
Interstitial Hyperthermia treatments are performed under the
supervision of a radiation oncologist who has been
adequately trained in either brachytherapy and/or theory
and clinical practice of interstitial hyperthermia. The physician is responsible for all clinical aspects of the hyperthermia
treatment (e.g., diagnosis, imaging, patient selection,
treatment prescription, fractionation, documentation).
The physician is responsible for implantation of an appropriate high-quality hyperthermia catheters implant. This
includes complete coverage of the target volume, protection
of organs at risk, and optimal separation and parallel orientation of catheters. The physician should understand the limitations of interstitial heating technology when placing the
implant catheters, to ensure optimal insertion length, alignment, and density for both radiation and hyperthermia considerations. In case of a challenging location, the physician
can invite a surgeon to place the implant catheters. Further,
the physician also takes care of additional medications for
pain management and breakthrough pain if needed.

(f) Anesthetists
When sedation of the patient is required, an anesthetist performs all relevant actions. A potential assistant must be formally trained in anesthesia.

(g) Arranging substitutes
As in many other clinical treatments, two of the previously
described responsible professionals must be present at the
beginning of each treatment session in order to take care of
the patient, to control the hyperthermia device, and to guarantee correct implementation and verification of all aspects
of the standard operational procedure (SOP). During treatment, one person might be sufficient if the other is available
on call. When interstitial hyperthermia is applied in combination with chemotherapy, a second person is responsible for
the chemotherapy application as described in the SOP for
chemotherapy.

IV-B treatment documentation
(c) Physicists/engineers
An adequately trained physicist or engineer is responsible for
the physical and technical aspects of the hyperthermia system (e.g., quality assurance and consistency checks, specifying the technical treatment parameters, intervention in case
of technical failures, phantom measurements, physical–technical part of the treatment planning) as described in this
document. In the preplanning phase, the physicist/engineer
must always advise the initial setup with the oncologist,
which defines the desired catheter positions and optimized
power delivery preplan.

(d) Technicians
The interstitial hyperthermia treatment can be assigned to a
hyperthermia trained assistant, for example a Radiation
Therapist or Radiographer under the direct supervision of a
physician and physicist. The technical assistant should be
specifically trained in the application of interstitial hyperthermia, with minimum training defined in section a) above. If
the hyperthermia equipment is operated by a technician, the
responsible physicist must be on-call and ready to take direct
action (maximum acceptable response time 5 min).

(e) Nurses
Nurses can support a medical technician to perform interstitial hyperthermia treatments after completing a training program. In most institutes, nurses are involved in the
preparation of patients for the hyperthermia treatment and
are responsible for the well-being of the patient (e.g., assist
with placement of interstitial catheters for applicators and

Treatment documentation varies for different complexity levels of clinical use of IHT. The minimum data set required to
reconstruct the treatment quality of ‘a standard treatment’ is
defined below. Multicenter trials and dose effect studies generally require a higher level of documentation as summarized
in Appendix A.
Interstitial hyperthermia presents an opportunity for temperature measurement directly within and adjacent to
tumors at depth which is generally not possible with superficial temperature monitoring. Rigorous temperature measurement throughout the treatment region is encouraged,
balanced with practical treatment considerations including
the total number of catheters required for radiation treatment and temperature probe placement.
Temperature data are preferably reported using maximal,
minimal and average temperatures Tmax, Tmin, Tave, and the
temperature parameters T10, T50, and T90, which are the temperatures achieved in 10%, 50% and 90% of (tumor-related)
measured points, respectively. These parameters give a fair representation of the temperature distribution during treatment
when a sufficient number of temperatures are monitored with
appropriate spatial sampling as described in the clinical study
protocol. Thus the number of sensors and the volume enclosed
by the sensors in relation to the target volume should be
recorded to reflect the quality of the temperature dosimetry.
When analyzing the achieved temperatures during IHT,
attention must be given to the position of the thermal sensors
with respect to the applicators. Temperatures recorded using
sensors placed separately in tissue between sensors typically
correlate with cold spots, giving values close to Tmin and T90.
Sensors integrated within or adjacent to the applicators
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generally provide information about maximal temperatures
Tmax and T10. Moreover, there are variations of temperature
along the length of the applicators so that higher quality dosimetry results from increasing the number of measurement
locations along each temperature monitoring catheter as well
as the number of probes/catheters. Placement of temperature
points and mapping to include tumor periphery at the distal
and proximal extent of implant, and within the implant interior are all critical to assess the quality of delivered treatment.
However, the perimeter of tumors is generally well-perfused
making those tissues more sensitive to radiation or chemotherapy alone. So the clinical impact of adding IHT may have
more importance based on the temperatures within the more
necrotic portions of the tumor that would be more resistant
to radiation or chemotherapy.

References
[1]
[2]
[3]
[4]
[5]

[6]

[7]

[8]

Minimum requirements for data reporting
All treatment relevant system control parameters (e.g.,
power, reflection, etc.) as well as all temperature measurement values must be stored at regular time intervals, for
example, every five minutes. Changes to the treatment
parameters must be documented with chronological reference. Temperatures must be documented in a manner that
they can be related chronologically to the corresponding
measurement location. Further, logging must be performed
of power-related pain, pain caused by the position of the
applicator or the applicator itself, treatment interruptions or
early termination. Acute and late toxicities must also be
recorded. Storing treatment data should preferably follow a
joint standard format. The published data standard for the
storage and interchange of hyperthermia clinical data could
serve as a starting point to address this issue [12].

Disclaimer
This publication is based on literature and other sources of
information judged to be reliable by the authors representing the ESHO-TC. However, the authors, ESHO-TC and editors
disclaim any warranty or liability based on or relating to the
contents of this publication. The authors and ESHO-TC do
not endorse any specific products, manufacturers, or suppliers. Nothing in this publication should be interpreted as
implying such endorsement. Several companies were invited
to provide feedback on the document but have not participated actively either at ESHO-TC meetings or in the writing
of this document. The authors and ESHO-TC alone are
responsible for the content and writing of this paper.

Disclosure statement

[9]

[10]

[11]
[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

No potential conflict of interest was reported by the authors.
[20]

ORCID
H. Dobsıcek Trefna
http://orcid.org/0000-0001-6025-0819
S. S. Gordeyev
http://orcid.org/0000-0002-9303-8379
http://orcid.org/0000-0002-5025-6317
P. R. Stauffer
http://orcid.org/0000-0002-7474-0533
J. Crezee

287

[21]

IAH. Available from: http://www.hyperthermie.org.
ESHO. Available from: www.esho.info
STM. Available from: http://www.thermaltherapy.org/eBusSFTM/.
Bruggmoser G. Some aspects of quality management in deep
regional hyperthermia. Int J Hyperther. 2012;28:562–569.
Bruggmoser G, Bauchowitz S, Canters R, et al. Guideline for the
clinical application, documentation and analysis of clinical studies
for regional deep hyperthermia. Strahlenther Onkol. 2012;188:
198–211.
Dobsicek Trefna H, Crezee H, Schmidt M, et al. Quality assurance
guidelines for superficial hyperthermia clinical trials: I. Clinical
requirements. Int J Hyperthermia. 2017;33:471–482.
Dobsicek Trefna H, Crezee J, Schmidt M, et al. Quality assurance
guidelines for superficial hyperthermia clinical trials: II. Technical
requirements for heating devices. Strahlenther Onkol. 2017;193:
351–366.
Emami B, Stauffer P, Dewhirst MW, et al. RTOG quality assurance
guidelines for interstitial hyperthermia. Int J Radiat Oncol Biol
Phys. 1991;20:1117–1124.
Stauffer PR, Diederich CJ, Seegenschmiedt MH. Interstitial heating
technologies. In: Seegenschmiedt MH, Fessenden P, Vernon CC,
editors. Thermoradiotherapy and thermochemotherapy: Volume
1, Biology, Physiology and Physics. Berlin, New York: SpringerVerlag; 1995. p. 279–320.
Visser AG, Chive M, Hand MW, et al. Interstitial and intracavitary
hyperthermia. A Task Group Report of the European Society for
Hyperthermic Oncology in cooperation with a COMAC-BME
Concerted Action within the 4th Medical and Health Research
Programme of the European Commission. Rome: Postgraduate
school of Medical Physics University of Rome Tor Vergata: 1993.
Hand JW, Lagenduk JJW, Andersen JB, et al. Quality Assurance
Guidelines for Esho Protocols. Int J Hyperther. 1989;5:421–428.
Sapareto SA, Corry PM. A proposed standard data file format for
hyperthermia treatments. Int J Radiat Oncol Biol Phys. 1989;16:
613–627.
Datta NR, Rogers S, Klingbiel D, et al. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network
meta-analyses. Int J Hyperthermia. 2016;32:809–821.
Issels R, Kampmann E, Kanaar R, et al. Hallmarks of hyperthermia
in driving the future of clinical hyperthermia as targeted therapy:
translation into clinical application. Int J Hyperthermia. 2016;32:
89–95.
Frey B, Ruckert M, Deloch L, et al. Immunomodulation by ionizing
radiation-impact for design of radio-immunotherapies and for
treatment of inflammatory diseases. Immunol Rev. 2017;280:
231–248.
Dewhirst MW, Stauffer PR, Das SK, et al. Hyperthermia In:
Gunderson L, Tepper J, editors. Clinical radiation oncology. 4th
ed. Philladelphia: Elsevier; 2016. p. 381–398.
Hoffman RM, Monga M, Elliott SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst
Rev. 2012(9);CD004135.
Dewhirst MW, Vujaskovic Z, Jones E, et al. Re-setting the biologic
rationale for thermal therapy. Int J Hyperthermia. 2005;21:
779–790.
Leopold KA, Dewhirst MW, Samulski TV, et al. Cumulative minutes
with T90 greater than Tempindex is predictive of response of
superficial malignancies to hyperthermia and radiation. Int J
Radiat Oncol Biol Phys. 1993;25:841–847.
Oleson JR, Samulski TV, Leopold KA, et al. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for
thermal goals of treatment. Int J Radiation Oncol Biol Phys. 1993;
25:289–297.
van Rhoon GC. Is CEM43 still a relevant thermal dose parameter
for hyperthermia treatment monitoring?. Int J Hyperthermia.
2016;32:50–62.

288

[22]

[23]

[24]
[25]

[26]
[27]

[28]

[29]

[30]

[31]

[32]
[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

 TREFNA
 ET AL.
H. DOBSICEK

Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding
normal tissue in vivo. Int J Radiat Oncol Biol Phys. 1980;6:
1507–1517.
Hulshof MCCM, Raaymakers BW, Lagendijk JJW, et al. A feasibility
study of interstitial hyperthermia plus external beam radiotherapy
in glioblastoma multiforme using the Multi Electrode Current
Source (MECS) system. Int J Hyperthermia. 2004;20:451–463.
Overgaard J. The current and potential role of hyperthermia in
radiotherapy. Int J Radiat Oncol Biol Phys. 1989;16:535–549.
Adibzadeh F, Paulides MM, van Rhoon GC. SAR thresholds for
electromagnetic exposure using functional thermal dose limits.
Int J Hyperthermia. 2018;34:1248–1254.
Stauffer PR. Evolving technology for thermal therapy of cancer.
Int J Hyperthermia. 2005;21:731–744.
Seegenschmiedt MH, Sauer R. Interstitial and intracavitary thermoradiotherapy. Berlin Heidelberg New York London, Paris,
Tokyo, Hong Kong Barcelona, Budapest: Springer-Verlag; 1993.
Ryan TP. Comparison of six microwave antennas for hyperthermia
treatment of cancer: SAR results for single antennas and arrays.
Int J Radiation Oncol Biol Phys. 1991;21:403–413.
Panjehpour M, Overholt BF, Milligan AJ, et al. Nd:YAG laserinduced interstitial hyperthermia using a long frosted contact
probe. Lasers Surg Med. 1990;10:16–24.
Astrahan MA, Norman A. A localized current field hyperthermia
system for use with 192-iridium interstitial implants. Med Phys.
1982;9:419–424.
Corry PM, Martinez A, Armour EP, et al. Simultaneous hyperthermia and brachytherapy with remote afterloading. In: Martinez AA,
Morton CT, Mould RF, editors. Brachytherapy HDR and LDR.
Proceedings of the meeting “Remote Afterloading: State of the
Art”; Colombia, MD, Dearborn, MI: Nucletron Corp; 1990. p.
193–204
Visser AG, Deurloo IKK, Levendag PC, et al. An Interstitial hyperthermia system at 27-Mhz. Int J Hyperthermia. 1989;5:265–276.
Kaatee RSJP, Crezee H, Kanis BP, et al. Spatial temperature control
with a 27 MHz current source interstitial hyperthermia system. Int
J Radiation Oncol Biol Phys. 1997;37:189–197.
Van der Koijk JF, Lagendijk JJW, Crezee J, et al. The influence of
vasculature on temperature distributions in MECS interstitial
hyperthermia: importance of longitudinal control. Int J
Hyperthermia. 1997;13:365–385.
Lesnicar H, Budihna M, Handl-Zeller L, et al. Clinical experience
with water-heated interstitial hyperthermia system. Acta Chir
Austriaca. 1992;24:214–216.
DeFord JA, Babbs CF, Patel UH, et al. Effective estimation and
computer control of minimum tumour temperature during conductive interstitial hyperthermia. Int J Hyperthermia. 1991;7:
441–453.
Stauffer PR, Cetas TC, Fletcher AM, et al. Observations on the use
of ferromagnetic implants for inducing hyperthermia. IEEE Trans
Biomed Eng. 1984;31:76–90.
Tucker RD, Platz CE, Huidobro C, et al. Interstitial thermal therapy
in patients with localized prostate cancer: histologic analysis.
Urology. 2002;60:166–169.
Patel UH, DeFord JA, Babbs CF. Computer-aided design and
evaluation of novel catheters for conductive interstitial hyperthermia. Med Biol Eng Comput. 1991;29:25–33.
Prionas SD, Kapp DS, Goffinet DR, et al. Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the
treatment of carcinoma of the prostate. Int J Radiat Oncol Biol
Phys. 1994;28:151–162.
Mack CF, Stea B, Kittelson JM, et al. Interstitial thermoradiotherapy with ferromagnetic implants for locally advanced and recurrent neoplasms. Int J Radiat Oncol Biol Phys. 1993;27:109–115.
Lagendijk JJW, Visser AG, Kaatee RSJP, et al. Interestitial hyperthermia & treatment planning: the 27 MHz multi-electrode current source method. Nucletron-Odelft Activity Report No 6; 1995.
p. 83–90.

[43]

[44]

[45]

[46]
[47]

[48]

[49]

[50]

[51]

[52]
[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

Diederich CJ, Khalil IS, Stauffer PR, et al. Direct-coupled interstitial
ultrasound applicators for simultaneous thermobrachytherapy: a
feasibility study. Int J Hyperthermia. 1996;12:401–419.
Diederich CJ. Ultrasound applicators with integrated cathetercooling for interstitial hyperthermia: theory and preliminary
experiments. Int J Hyperthermia. 1996;12:279–297.
Nau WH, Diederich CJ, Stauffer PR. Directional power deposition
from direct-coupled and catheter-cooled interstitial ultrasound
applicators. Int J Hyperthermia. 2000;16:129–144.
Stauffer PR, Goldberg SN. Introduction: thermal ablation therapy.
Int J Hyperthermia. 2004;20:671.
Diederich CJ. Thermal ablation and high-temperature thermal
therapy: overview of technology and clinical implementation. Int
J Hyperthermia. 2005;21:745–753.
Pieters BR, van der Grient JN, Blank LE, et al. Minimal displacement of novel self-anchoring catheters suitable for temporary
prostate implants. Radiother Oncol. 2006;80:69–72.
van der Koijk JF, Crezee J, Lagendijk JJW. Thermal properties of
capacitively coupled electrodes in interstitial hyperthermia. Phys
Med Biol. 1998;43:139–153.
Kukielka AM, Hetnal M, Brandys P, et al. Interstitial hyperthermia
of the prostate in combination with brachytherapy: an evaluation
of feasibility and early tolerance. Strahlenther Onkol. 2013;189:
467–475.
Hand JW, Trembly BS, Prior MV. Physics of interstitial hyperthermia: radiofrequency and hot water tube techniques. In: Urano M,
Douple E, editors. Hyperthermia and oncology, vol 3. Interstitial
Hyperthermia. Zeist: VSP; 1991. p. 99–134.
Handl-Zeller L, editor. Interstitial hyperthermia. Wien, New York:
Springer-Verlag; 1992.
Strohbehn JW. Interstitial techniques for hyperthermia. In: Field
SB, Franconi C, editors. Physics and technology of hyperthermia.
Dordrecht, Boston, Lancaster: Martinus Nijhoff Publishers; 1987. p.
211–240.
Vrba J, Franconi C, Lapes M. Theoretical limits for the penetration
depth of intracavitary applicators. Int J Hyperthermia. 1996;12:
737–742.
Dutz S, Hergt R. Magnetic nanoparticle heating and heat transfer
on a microscale: basic principles, realities and physical limitations
of hyperthermia for tumour therapy. Int J Hyperthermia. 2013;29:
790–800.
Cristoforetti L, Pontalti R, Cescatti L, et al. Quantitative colorimetric analysis of liquid crystal films (LCF) for phantom dosimetry in
microwave hyperthermia. IEEE Trans Biomed Eng. 1993;40:
1159–1165.
Babij TM, Hagmann MJ, Gottlieb CF, et al. Evaluation of heating
patterns of microwave interstitial applicators using miniature
electric field and fluoroptic temperature probes. Int J
Hyperthermia. 1991;7:485–492.
Deardorff DL, Diederich CJ, Nau WH. Control of interstitial thermal coagulation: comparative evaluation of microwave and ultrasound applicators. Med Phys. 2001;28:104–117.
Wilkinson DA, Saylor TK, Shrivastava PN, et al. Calorimetric evaluation of antennas used for microwave interstitial hyperthermia.
Int J Hyperthermia. 1990;6:655–663.
Hartsgrove G, Kraszewski A, Surowiec A. Simulated biological
materials for electromagnetic radiation absorption studies.
Bioelectromagnetics. 1987;8:29–36.
de Bree J, van der Koijk JF, Lagendijk JJ. A 3-D SAR model for
current source interstitial hyperthermia. IEEE Trans Biomed Eng.
1996;43:1038–1045.
Prakash P, Salgaonkar VA, Diederich CJ. Modelling of endoluminal
and interstitial ultrasound hyperthermia and thermal ablation:
applications for device design, feedback control and treatment
planning. Int J Hyperthermia. 2013;29:296–307.
Pisa S, Cavagnaro M, Piuzzi E, et al. Power density and temperature distributions produced by interstitial arrays of sleeved-slot
antennas for hyperthermic cancer therapy. Ieee Trans Microwave
Theory Techn. 2003;51:2418–2426.

INTERNATIONAL JOURNAL OF HYPERTHERMIA

[64]

[65]

[66]

[67]

[68]

[69]

[70]

[71]
[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]
[80]

[81]

[82]

[83]

Salgaonkar VA, Prakash P, Diederich CJ. Temperature superposition for fast computation of 3D temperature distributions during
optimization and planning of interstitial ultrasound hyperthermia
treatments. Int J Hyperthermia. 2012;28:235–249.
Raaymakers BW, Van Vulpen M, Lagendijk JJ, et al. Determination
and validation of the actual 3D temperature distribution during
interstitial hyperthermia of prostate carcinoma. Phys Med Biol.
2001;46:3115–3131.
van Vulpen M, Raaymakers BW, Lagendijk JJ, et al. Three-dimensional controlled interstitial hyperthermia combined with radiotherapy for locally advanced prostate carcinoma–a feasibility
study. Int J Radiat Oncol Biol Phys. 2002;53:116–126.
Scott SJ, Prakash P, Salgaonkar V, et al. Interstitial ultrasound
ablation of tumors within or adjacent to bone: contributions of
preferential heating at the bone surface. Energy-based Treatment
of Tissue and Assessment VII. Proc. SPIE. 2013;8584.
Chen X, Diederich CJ, Wootton JH, et al. Optimisation-based thermal treatment planning for catheter-based ultrasound hyperthermia. Int J Hyperthermia. 2010;26:39–55.
Myerson RJ, Moros EG, Diederich CJ, et al. Components of a
hyperthermia clinic: recommendations for staffing, equipment,
and treatment monitoring. Int J Hyperthermia. 2014;30:1–5.
Diederich C. Endocavitary and catheter-based ultrasound devices.
In: Moros E, editor. Physics of thermal therapy. Boca Raton: CRC
Press; 2013.
Pyrexar Medical Inc. “BSD-500 Features”. [cited 2019 Jan 8]
Available from: http://www.pyrexar.com/hyperthermia/bsd-500.
Crezee J, der Koijk v, Kaatee Rsjp JF, Lagendijk JJW. Implications
of using thermocouple thermometry in 27 MHz capacitively
coupled interstitial hyperthermia. Phys Med Biol. 1997;42:
637–650.
Stuecklschweiger G, Arian-Schad KS, Kapp DS, et al. Analysis of
temperature distributions of interstitial hyperthermia using a hot
water system. Int J Radiat Oncol Biol Phys. 1993;26:891–895.
Wootton JH, Prakash P, Hsu IC, et al. Implant strategies for endocervical and interstitial ultrasound hyperthermia adjunct to HDR
brachytherapy for the treatment of cervical cancer. Phys Med
Biol. 2011;56:3967–3984.
Diederich CJ, Wootton J, Prakash P, et al. Catheter-based ultrasound hyperthermia with HDR brachytherapy for treatment of
locally advanced cancer of the prostate and cervix. Proc SPIE Int
Soc Opt Eng. 2011;7901:79010O.
Salgaonkar VA, Diederich CJ. Catheter-based ultrasound technology for image-guided thermal therapy: current technology and
applications. Int J Hyperthermia. 2015;31:203–215.
Commission IE. IEC 61161 Ultrasonics - Power measurement Radiation force balances and performance requirements Edition
3.0. Geneva, Switzerland 2013.
Wootton JH, Hsu IC, Diederich CJ. Endocervical ultrasound applicator for integrated hyperthermia and HDR brachytherapy in the
treatment of locally advanced cervical carcinoma. Med Phys.
2011;38:598–611.
Crezee H, Inman BA. The use of hyperthermia in the treatment of
bladder cancer. Int J Hyperthermia. 2016;32:349–350.
van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for
non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32:
351–362.
Sousa A, Pineiro I, Rodriguez S, et al. Recirculant hyperthermic
IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk nonmuscle-invasive bladder cancer. Int J Hyperthermia. 2016;32:
374–380.
Stauffer PR, van Rhoon GC. Overview of bladder heating technology: matching capabilities with clinical requirements. Int J
Hyperthermia. 2016;32:407–416.
Schooneveldt G, Bakker A, Balidemaj E, et al. Thermal dosimetry
for bladder hyperthermia treatment. An overview. Int J
Hyperthermia. 2016;32:417–433.

[84]

[85]

[86]
[87]
[88]
[89]
[90]

[91]

[92]

[93]

289

van der Heijden AG, Dewhirst MW. Effects of hyperthermia in
neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32:434–445.
Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC
in the Netherlands: nationwide long-term outcome following the
Dutch protocol. Ann Surg Oncol. 2013;20:4224–4230.
Eight Medical Corporation.
Therma Solutions Inc. [cited 2018 Jan 8]. Available from: https://
www.thermasolutions.com/.
Gamida. [cited 2018 Jan 8]. Available from: http://www.gamida.
net/.
Rand. [cited 2018 Jan 8]. Available from: http://rand-biotech.com/.
Diederich CJ, Hynynen K. The development of intracavitary ultrasonic applicators for hyperthermia: a design and experimental
study. Med Phys. 1990;17:626–634.
Hurwitz MD, Hansen JL, Prokopios-Davos S, et al. Hyperthermia
combined with radiation for the treatment of locally advanced
prostate cancer: long-term results from Dana-Farber Cancer
Institute study 94-153. Cancer. 2011;117:510–516.
Hurwitz MD, Kaplan ID, Hansen JL, et al. Hyperthermia combined
with radiation in treatment of locally advanced prostate cancer is
associated with a favourable toxicity profile. Int J Hyperthermia.
2005;21:649–656.
Hurwitz MD, Kaplan ID, Hansen JL, et al. Association of rectal toxicity with thermal dose parameters in treatment of locally
advanced prostate cancer with radiation and hyperthermia. Int J
Radiat Oncol Biol Phys. 2002;53:913–918.

Appendix A
Analysis and documentation of treatments mandatory
for institutes participating in clinical trials and
recommended in general
Temperature data are preferably reported maximal, minimal and average
temperatures Tmax, Tmin, Tave, and the temperature parameters T10, T50,
and T90, which are the temperatures achieved in 10%, 50% and 90% of
(tumor-related) measured points, respectively. These parameters give a
fair representation of the temperature distribution during treatment
when a sufficient number of temperatures are monitored with appropriate spatial sampling as described in the clinical study protocol. Thus, the
number of sensors and the volume enclosed by the sensors in relation
to the target volume should be recorded to reflect the quality of the
thermal dosimetry (e.g., does it include peripheral as well as central
tumor monitoring). Thermal dose accumulates as a nonlinear function of
temperature and linear function of time and is preferably reported as
Cumulative Equivalent Minutes (CEM) T50 and T90 at 43  C, that is,
CEM43T50 and CEM43T90 respectively [4,5,21].
The exact evaluation procedure to be followed is prescribed by the
particular study protocols, but in general good documentation encompasses the following items:
Treatment efficacy:
Tumor response: complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) following the international definitions for these evaluation criteria.
Tumor regression grade (TRG) according to Mandard or Dworak scale
for patients undergoing tumor resection after initial treatment with
hyperthermia.
Tumor downstaging by T and N parameters using the latest TNM
classification.
Survival analysis following the international practice and definitions
Toxicity using the latest version of the standard CTCAE scoring list:
Acute Toxicity (treatment-related toxicity occurring during treatment
and/or within 3 months after completing the treatment)
Late toxicity (treatment related toxicity persisting or occurring after 3
months after completing the treatment)

Mild pain

Brief partial seizure; no loss of
consciousness

Minimal symptoms, intervention
not indicated

Localized facial edema

5–10% inter-limb discrepancy in
volume or circumference at
point of greatest visible difference; swelling or obscuration of anatomic
architecture on
close inspection

Swelling or obscuration of anatomic architecture on
close inspection

Abdominal pain

Seizure

Burn

Edema face

Edema limbs

Edema trunk

Asymptomatic or mild symptoms; intervention
not indicated
Rectal discomfort, intervention
not indicated

Increase of <4 stools per day
over baseline; mild increase
in ostomy output compared
to baseline

Mild pain

Mucositis oral

Diarrhea

Oral pain

Proctitis

Symptomatic (e.g., dry or thick
saliva) without significant
dietary alteration; unstimulated saliva flow >0.2 ml/min

Dry mouth

Soft tissue necrosis (Head/Neck/
Abdominal/Lower limb/Upper
limb/Pelvic)

Pain of skin

Removable, adjustments allow
therapy to be completed
as planned
Mild Pain

Hot spot/heat build ups

I

Moderate pain; limiting instrumental ADL

Moderate symptoms; oral intake alterations (e.g., copious water, other lubricants, diet limited to purees and/or
soft, moist foods); unstimulated saliva
0.1 to 0.2 ml/min
Moderate pain or ulcer that does not
interfere with oral intake; modified
diet indicated
Symptomatic (e.g., rectal discomfort,
passing blood or mucus); medical
intervention indicated; limiting instrumental ADL
Increase of 4–6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting
instrumental ADL

Moderate localized facial edema; limiting
instrumental ADL
>10–30% inter-limb discrepancy in volume or circumference at point of
greatest visible difference; readily
apparent obscuration of anatomic
architecture; obliteration of skin folds;
readily apparent deviation from normal anatomic contour; limiting instrumental ADL
readily apparent deviation from normal
anatomic contour; limiting instrumental ADL
Local wound care; medical intervention
indicated (e.g., dressings or topical
medications)

Medical intervention, minimal debridement indicated

Power or temperature reduction necessary, continuation of therapy
is possible
Moderate pain; limiting instrumental
Activities of Daily Living (ADL)
Moderate pain; limiting instrumental
Activities of Daily Living (ADL)
Brief generalized seizure

II

Increase of 7 stools per day over
baseline; hospitalization indicated; severe increase in ostomy
output compared to baseline;
limiting self care ADL
Severe pain; limiting self care ADL

Severe symptoms; fecal urgency or
stool incontinence; limiting self
care ADL

Severe pain; interfering with
oral intake

Gross deviation from normal anatomic contour; limiting self
care ADL
Operative debridement or other
invasive intervention indicated
(e.g., tissue reconstruction, flap,
or grafting)
Inability to adequately aliment
orally; tube feeding or TPN indicated; unstimulated saliva
<0.1 ml/min

Severe swelling; limiting self
care ADL
>30% inter-limb discrepancy in
volume; gross deviation from
normal anatomic contour; limiting self care ADL

New onset seizures (partial or generalized); multiple seizures despite medical intervention
Moderate or majordebridement or
reconstruction indicated

Severe pain; limiting self care ADL

Severe pain; limiting self care ADL

Early termination of therapy required

III

–

–

–

Life-threatening consequences; urgent intervention indicated

Life-threatening consequences; urgent intervention indicated
Life-threatening consequences; urgent intervention indicated

–

–

Death

Death

Death

–

Death

–

–

Life-threatening consequences; urgent intervention indicated

CTCAE v5.0

–

CTCAE v5.0
(continued)

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

CTCAE v5.0

Death

Death

–

–

CTCAE v5.0

QMHT

Reference Standard

Life-threatening consequences; prolonged repetitive seizures
Life threatening consequences; skin necrosis or ulceration of full thickness
dermis; spontaneous
bleeding from involved
site; skin graft indicate
–

–

V
Death

Impossibility of continuing
next treatments, refusal of
further therapy
–

IV

Table (A-1). Classification of hyperthermia specific side effects according to Common Toxicity Criteria Adverse Events (CTCAE) v5.0 and Quality Management in Hyperthermia (QMHT).

Degree
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CTCAE v5.0

CTCAE v5.0

CTCAE v5.0
CTCAE v5.0

CTCAE v5.0

Reference Standard
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Further, each clinical study protocol under the auspices of ESHO will
be executed in accordance to the latest ESHO quality assurance guidelines and will include the following statements:
a.

–

Death

Urinary, suprapubic or intermittent catheter placement not
indicated; able to void with
some residual
Occasional (e.g., with coughing,
sneezing, etc.), pads
not indicated
Urinary retention

Urinary incontinence

Mild pain
Present
Urinary tract pain
Urinary frequency/urgency

Spontaneous; pads indicated; limiting
instrumental ADL

Life-threatening consequences; organ failure; urgent
operative intervention indicated
–
Elective invasive intervention indicated; substantial loss of
affected kidney function
or mass
Intervention indicated (e.g., clamp,
collagen injections); operative
intervention indicated; limiting
self care ADL

–
–
–
–
Severe pain; limiting self care ADL
–

V

Death

III

IV

Moderate hematuria; moderate increase
in frequency, urgency, dysuria, nocturia or incontinence; urinary catheter
placement or bladder irrigation indicated; limits instrumental ADL
Moderate pain; limiting instrumental ADL
Limiting instrumental ADL; medical management indicated
Placement of urinary, suprapubic or intermittent catheter placement indicated;
medication indicated

II
I

Microscopic hematuria; minimal
increase in frequency,
urgency, dysuria, or nocturia;
new onset of incontinence
Cystitis noninfective

Degree

Gross hematuria; transfusion, IV
medications or hospitalization
indicated; elective invasive intervention indicated

Life-threatening consequences; urgent invasive intervention indicated

b.

Table A-1. Continued.
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c.

An audit of the participating institute will be performed to validate
that documentation is in accordance with the study protocol.
A site visit will be performed by a member of the ESHO-TC.
Selection of this person will be in close cooperation with the principal investigator of the study, the institute’s local study coordinator,
the chair of the Medical Committee of ESHO, and the chair of the
ESHO-TC.
The institution that will be visited is responsible for the support
(traveling, lodging and time) of the auditor.

The following points should be considered for evaluating clinically
relevant hyperthermia studies:
1.

Patient selection for trial participation
Before starting the therapy, a qualified physician must define the
indications for the hyperthermia treatment, regarding the inclusion
and exclusion criteria as defined in either local or multi-institutional protocols.
2. Documentation
The documentation includes a clinical part, as well as a
physical–technical part. When the patient agrees to participate in
the clinical study, a hard copy of the informed consent signed by
the patient and MD must be stored. Duration of storage is prescribed by national guidelines. The local situation of the designated
treatment field should be documented with pictures.
For patient-related medical data, protection regulations and doctor–patient confidentiality apply. Availability and readability of the
treatment-relevant data must be ensured for the period specified
by the clinical protocol and (inter)national law.
2.1. Physical–technical documentation
All treatment relevant system control parameters (e.g., power, reflection, etc.) as well as all temperature measurement values must be
stored electronically in a retrievable fashion. Changes to the treatment parameters must be documented with chronological reference.
Temperatures must be documented in a manner that they can be
related chronologically to the corresponding measurement location
and power delivery parameters.
(a) Data log of the course of treatment
Logging must be performed of: all temperatures, power, complaints
caused by position or power of the applicator, and treatment interruptions or early termination.
(b) Data log of the hyperthermia system
All hyperthermia device-related quality assurance data must be documented in the device logbook. The recordings must be according to
the existing national law (e.g., the German Medizinprodukte Gesetz
(MPG). Storing treatment data should preferably follow a joint standard format.
2.2. Clinical documentation
a. Informed consent with a list of potential side effects of adjuvant
hyperthermia is mandatory (according to national law).
b. Clinical Setup - Clinical documentation should describe the positions of patient, applicator, and temperature probes to allow reproduction of the treatment setup. For additional interstitial sensors,
additional CT, MRI and/or US imaging is recommended.
c. Medications (including cytotoxic drugs), concurrent radiotherapy,
and any other concurrent medical treatment.
d. Treatment related toxicity must be documented with a chronological reference to the hyperthermia treatment. Side effects that
are specifically caused by hyperthermia are primarily unwanted
high temperatures in the skin or nontarget tissues, especially in
patients with compromised temperature sensitivity, for example in
polyneuropathy or near surgical scars. Moderate temperatures may
be accompanied by false sensations, feelings of urgency for bladder or bowel release, or skin irritation, pain, and/or local edema. In
case of sustained overheating of tissue, tissue damage and necrosis
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may result. The temperature threshold for such irreversible damage
is approximately 44–46  C and 120–240 CEM43C thermal dose
depending on the tissue type. Specific side effects are given in
Table A-1. Hyperthermia treatment (in terms of these guidelines) is
not a single therapy mode, but supplements systemic chemotherapy or radiation therapy. Side effects of the combined treatment
therefore correspond primarily with intensification of the spectrum
of side effects of chemotherapy or radiation therapy alone.
Classifying the side effects should follow the latest version of the
internationally established and accepted scoring systems (Common
Terminology Criteria for Adverse Events (CTCAE) and Quality
Management in Hyperthermia (QMHT). Worst grade toxicity sustained up to 90 days from treatment initiation is classified as acute
toxicity. Worst grade toxicity sustained more than 90 days from
treatment initiation is classified as late toxicity. Physician reported
toxicity should be supplemented by patient reported outcomes
including quality of life using validated measures.
2.3 Standardization of the analysis of physical/technical treatment data
In order to create comparable analysis for all study participants, the
relevant data are extracted and, as far as possible, analyzed using
standard software.

Appendix B: Overview of historical and current
devices for interstitial heating
Interstitial applicators in use today consist of microwave antennas (MW),
resistively coupled radiofrequency local current field electrodes (RF-LCF),
capacitively coupled radiofrequency catheter-based electrodes (RF-CC),
ultrasound transducers (US), and various hot source techniques (HS). In
general, these devices deposit energy within a limited volume of tissue
close to the heating device(s). The operating principles of various systems for interstitial heating have been reviewed previously ([9,10,51,70]).
Interstitial microwave antennas have been constructed with numerous variations of the radiating structure in attempts to optimize performance for different tissue sites [15,40]. The most commonly available
commercial applicator is the BSD-500 – Pyrexar modified dipole antenna
model MA-251 (1.20mm OD) operating at 915 MHz [71]. The radiating
portion is fixed in length as determined by wavelength constraints of
915 MHz radiation. The applicator can be inserted within Nylon or
Celcon 15–15.5 gauge (1.74–1.8 mm OD) or six French brachytherapy
implant catheters typically placed during an High-Dose Rate (HDR)
brachytherapy implant procedure. For insertion depths greater than
6 cm, the effectively heated portion (>10–25% SAR contour) is approximately 5 cm along the distal length of implant, potentially extending
beyond the tip. For a typical implant, multiple applicators are inserted in
catheters around the periphery and 1.0–2.0 cm apart within the GTV.
Depending upon alignment and separation distance, the applicator can
be operated in synchronous or asynchronous mode at the discretion of
the physicist to maximize uniformity of SAR distribution and extent
tumor heating. However, care must be taken when the insertion depths
and insertion angles are unequal. In this situation and with tumor axial
dimensions greater than 3 cm, the more conservative asynchronous
approach is recommended. When operating in synchronous mode, the
phase of each applicator with respect to the others can be modified to
steer the overall SAR distribution within the target and obtain more
selective central array heating. Regardless of phase relationship, feedline
heating and radiation pattern as a function of insertion depth need to
be accommodated in the treatment plan, to best ensure targeted heating of the tumor volume and minimization of surrounding normal tissue
heating. MW compatible high resistance lead thermistor probes or fiberoptic probes are preferred, but thermocouples have also been used if
properly filtered and a minimum distance and perpendicular orientation
from the sources maintained.
Interstitial radiofrequency electrodes generate heating by resistive
losses of conduction currents between electrodes and can be divided in
two classes, resistively coupled radiofrequency local current field (RFLCF) electrodes which are in direct galvanic contact with the tissue and
capacitively coupled radiofrequency catheter-based electrodes (RF-CC).
RF-LCF electrodes relying on RF currents between metal electrodes are

straightforward in use and can be combined with simultaneous brachytherapy. The disadvantage is that the output of individual electrodes is
strongly dependent on the local electrical tissue properties and the location and alignment of adjacent electrodes [8]. Interstitial capacitively
coupled radiofrequency catheter-based electrodes were designed to
overcome this issue by using segmented bipolar electrodes operating
from within catheters. The impedance associated with the catheter wall
far exceeds the tissue impedance, so RF-CC electrodes are less sensitive
to heterogeneous tissue properties and parallel alignment, and multielectrode applicators were developed to achieve 3-D control over the
spatial power deposition [33,34,42]. Multi-junction thermocouple probes
are integrated into the electrodes and are used for treatment monitoring
and feedback [72]. Interstitial hot source techniques have not been used
extensively, but good temperatures have been reported by several
groups [36,41,73].
Interstitial ultrasound applicators are currently under investigation for
delivery of hyperthermia within an HDR implant [42]. The unique and
advantageous property of ultrasound devices is that the radiating transducer portion can be segmented into separate tubular radiating elements along the catheter length and even separate sectors around the
tube surface. Each sector or segment can be operated under individual
power control to tailor the SAR to fit the tumor target or in response to
dynamic tissue changes. The short wavelengths for 5–10 MHz radiators
ensure generation of well-directed energy patterns that are not susceptible to change from variations in insertion depth or alignment angle,
such as is common for RF and MW devices. Typical configurations are
four to five 10 mm long tubular transducers separated by 1 mm; radiating either 360 deg (circumferential) or 210 deg (directional) sonication
patterns. The directional devices can be steered or directed toward the
center of the target volume, while the dead-zone or inactive region with
zero energy output can be positioned to provide protection of sensitive
tissues such as rectum or bladder. Multiple transducer directional ultrasound devices have been used for treatment of prostate and cervical
cancers [74–76]. These interstitial ultrasound devices are larger than MW
antennas, and thus require slightly larger 13 or 14 g Celcon Flexi-Guide
brachytherapy (2.2–2.4 mm outside diameter (OD)) implant catheters,
compared to the 15–16 g commonly used for HDR brachytherapy. A
larger separation distance of 15–20 mm is tolerable between applicators
due to the 1/r radial propagation (versus 1/r2 for RF) which produces
enhanced penetration depth of ultrasound compared to microwave.
Larger devices (e.g., 4 mm OD) designed to fit within a standard HDR
tandem plastic catheter for the treatment of uterus and cervix, provide
directional and longitudinal control of power deposition to the cervix
[74–76]. It must be noted that ultrasound devices are generally more
complex to operate in that power levels must be controlled individually
to multiple elements after careful preplanning of the position and angle
of each implant catheter, and water-flow is required within each catheter. Multi-junction thermocouple probes within adjacent catheters can
be used for treatment monitoring and feedback. Instead of associating
individual transducer segments to an individual temperature sensor, the
starting shape of power deposition can be applied and adjusted in magnitude during the treatment as a simplification.
Quality assurance for ultrasound requires determination of the optimal driving frequency for the applicator and the efficiency of electrical
input to acoustic power output. This characterization is typically performed using an acoustic force-balance system [77]. The beam pattern
(equivalent to power deposition pattern) is typically measured in water
using a calibrated hydrophone and provides a direct representation of
the energy output pattern [45,78]. Further, tissue mimicking phantoms
for ultrasound can be used, either as a split phantom in conjunction
with an IR camera or using embedded temperature sensors for determination of the power deposition pattern.

Appendix C: Current devices for intracavitary and
intraluminal hyperthermia
As implied by the word intracavitary, hyperthermia is applied only to
heat tissues surrounding natural body cavities (i.e., bladder, rectum,
vagina, cervix, and esophagus) or within an intraoperative cavity such as
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treatment of metastatic spread of cancer cells within the abdomen.
Extensive descriptions of the methodology and prospects of heating
nonmuscle invasive bladder cancer have been published recently in a
special issue of the Int. J. of Hyperthermia (Vol 32, Iss 4). As discussed in
the literature, several commercial systems are available for applying
hyperthermia in combination with chemotherapy for treating nonmuscle invasive bladder cancer [79–84]. In addition, commercial systems
are available for applying hyperthermic intraperitoneal chemotherapy for
the treatment of metastatic spread of cancer cells within the abdomen
[85–89]. For both intracavitary hyperthermia methods, the quality of
treatment strongly depends on fluid circulation, control of the chemotherapy application, and the surgical procedure. Hence, specific quality
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assurance guidelines should be developed in due time for these treatment modalities.
Endorectal ultrasound devices have been developed specifically for
prostate hyperthermia [70,90] and evaluated in clinical studies [91,92].
With this technique, a linear array of 1.5 MHz tubular transducers with
individual power control provides longitudinal and angular control of
heating profiles 2–4 cm from the rectal wall – covering the entire prostate and seminal vesicles without an increase in rectal toxicity [93]. An
expandable water-cooling jacket was used to provide good coupling
and protection of the rectal wall. Quality assurance for intraluminal ultrasound devices follows the same principles as those for interstitial devices.

